Dr Reddy’s Bags Rights To Two More Biosimilars In Deal With Bio-Thera

Agreement Covers Stelara And Simponi Rivals In South-East Asia

 
• By Dave Wallace

India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.

The deal covers multiple markets in south-east Asia (Shutterstock)

More from Deals

More from Strategy